Phosphorylation at ser-181 of oncogenic KRAS is required for tumor growth

Cancer Research

Volumn 74, Issue 4, 2014, Pages 1190-1199

  Barceló, Carles ^a   Paco, Noelia ^a   Morell, Mireia ^b,c   Alvarez Moya, Blanca ^a,e   Bota Rabassedas, Neus ^a,f   Jaumot, Montserrat ^a   Vilardell, Felip ^d   Capella, Gabriel ^b,c   Agell, Neus ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c 08907 L'Hospitalet de Llobregat ^*  (United States)

^d UNIVERSITY OF LLEIDA   (Spain)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; HUMANS; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASMS; NIH 3T3 CELLS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SERINE;

EID: 84894236975     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1750     Document Type: Article

References (42)

1. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
2. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-65.
3. Downward J. Control of ras activation. Cancer Surv 1996;27:87-100.
4. Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Cancer Res 2012;72:2457-67.
5. Schubbert S, Shannon K, Bollag G. Hyperactive ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308.
6. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding ras: 'it ain't over' 'til it's over'. Trends Cell Biol 2000;10:147-54.
7. Marshall CJ. Ras effectors. Curr Opin Cell Biol 1996;8:197-204.
8. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 2011;13:39-51.
9. Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, et al. Ubiquitination of K-ras enhances activation and facilitates binding to select downstream effectors. Sci Signal 2011;4: ra13.
10. Yang MH, Nickerson S, Kim ET, Liot C, Laurent G, Spang R, et al. Regulation of RAS oncogenicity by acetylation. Proc Natl Acad Sci USA 2012;109:10843-8.
11. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989; 57:1167-77.
12. Silvius JR. Mechanisms of ras protein targeting in mammalian cells. J Membr Biol 2002;190:83-92.
13. Ballester R, Furth ME, Rosen OM. Phorbol ester-and protein kinase C-mediated phosphorylation of the cellular kirsten ras gene product. J Biol Chem 1987;262:2688-95.
14. Alvarez-Moya B, Lopez-Alcala C, Drosten M, Bachs O, Agell N. K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-ras activity and function. Oncogene 2010;29: 5911-22.
15. Lowry Oh, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
16. Guerrero S, Figueras A, Casanova I, Farre L, Lloveras B, Capella G, et al. Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J 2002; 16:1642-4.
17. Yuan J, Yan R, Kramer A, Eckerdt F, Roller M, Kaufmann M, et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004;23:5843-52.
18. Chu R, Terrano DT, Chambers TC. Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of mcl-1, promoting its degradation and freeing bak from sequestration. Biochem Pharmacol 2012;83:199-206.
19. Borgne A, Versteege I, Mahe M, Studeny A, Leonce S, Naime I, et al. Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment. Oncogene 2006;25:7361-72.
20. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, et al. PKC regulates a farnesyl-electrostatic switch on K-ras that promotes its association with bcl-XL on mitochondria and induces apoptosis. Mol Cell 2006;21:481-93.
21. Alvarez-Moya B, Barcelo C, Tebar F, Jaumot M, Agell N. CaM interaction and Ser181 phosphorylation as new K-ras signaling modulators. Small GTPases 2011;2:99-103.
22. Choi SH, Hyman T, Blumberg PM. Differential effect of bryostatin 1 and phorbol 12-myristate 13-acetate on HOP-92 cell proliferation is mediated by down-regulation of protein kinase cdelta. Cancer Res 2006;66:7261-9.
23. Gajate C, Matos-da-Silva M, Dakir el-H, Fonteriz RI, Alvarez J, Molli-nedo F. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene 2012;31:2627-39.
24. Abraham I, El Sayed K, Chen ZS, Guo H. Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs 2012;10:2312-21.
25. Lopez-Campistrous A, Song X, Schrier AJ, Wender PA, Dower NA, Stone JC. Bryostatin analogue-induced apoptosis in mantle cell lym-phoma cell lines. Exp Hematol 2012;40:646, 56.e2.
26. Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, et al. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-betaII depletion. Haematologica 2012;97:771-9.
27. Mohammad RM, Li Y, Mohamed AN, Pettit GR, Adsay V, Vaitkevicius VK, et al. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Pancreas 1999;19:353-61.
28. Conesa-Zamora P, Mollinedo F, Corbalan-Garcia S, Gomez-Fernandez JC. A comparative study of the effect of the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine and some homologous compounds on PKC alpha and PKC epsilon. Biochim Biophys Acta 2005;1687:110-9.
29. Zhou X, Arthur G. 1-O-octadecyl-2-O-methylglycerophosphocholine inhibits protein kinase C-dependent phosphorylation of endogenous proteins in MCF-7 cells. Biochem J 1997;324:897-902.
30. Liou JS, Chen JS, Faller DV. Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. J Cell Physiol 2004;198:277-94.
31. Kinoshita E, Kinoshita-Kikuta E, Koike T. Separation and detection of large phosphoproteins using phos-tag SDS-PAGE. Nat Protoc 2009;4:1513-21.
32. Van Itallie CM, Tietgens AJ, LoGrande K, Aponte A, Gucek M, Anderson JM. Phosphorylation of claudin-2 on serine 208 promotes membrane retention and reduces trafficking to lysosomes. J Cell Sci 2012;125:4902-12.
33. Jasinski P, Welsh B, Galvez J, Land D, Zwolak P, Ghandi L, et al. A novel quinoline, MT477: suppresses cell signaling through ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. Invest New Drugs 2008;26:223-32.
34. Jasinski P, Zwolak P, Terai K, Borja-Cacho D, Dudek AZ. PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-ras-mutated cancer via induction of apoptosis. Invest New Drugs 2011;29:33-40.
35. Xia S, Chen Z, Forman LW, Faller DV. PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1. Cell Signal 2009;21:502-8.
36. Shen L, Kim SH, Chen CY. Sensitization of human pancreatic cancer cells harboring mutated K-ras to apoptosis. PLoS ONE 2012;7: e40435.
37. Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, et al. Protein kinase C delta is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res 2011;71:2087-97.
38. Jeng HH, Taylor LJ, Bar-Sagi D. Sos-mediated cross-activation of wild-type ras by oncogenic ras is essential for tumorigenesis. Nat Commun 2012;3:1168.
39. Pal D, Outram SP, Basu A. Upregulation of PKCeta by PKCepsilon and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival. Biochim Biophys Acta 2013;1830:4040-5.
40. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012;11:937-57.
41. Barcelo C, Paco N, Beckett AJ, Alvarez-Moya B, Garrido E, Gelabert M, et al. Oncogenic K-ras segregates at spatially distinct plasma membrane signaling platforms according to its phosphorylation status. J Cell Sci 2013;126:4553-9.
42. Lopez-Alcala C, Alvarez-Moya B, Villalonga P, Calvo M, Bachs O, Agell N. Identification of essential interacting elements in K-ras/calmodulin binding and its role in K-ras localization. J Biol Chem 2008;283: 10621-31.